Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...
Streamlined pharmacologic recommendations challenge the stepwise approach for moderately to severely active disease.
TipRanks on MSN
SinoMab’s SM17 IND application for IBD accepted by NMPA
An update from SinoMab Bioscience Ltd. ( ($HK:3681) ) is now available. SinoMab BioScience Limited announced that its Investigational New Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback